In the course of recurrence or metastasis of breast cancer, hormone receptor expression was partly absent and the deletion rate of PR in recurrence or metastasis was higher than that of ER, which may be related to the heterogeneity of tumors and previous endocrine therapy. This evidence concerns the gene ESR1 and breast carcinoma.